Corindus Vascular Robotics (NYSE:CVRS) said today it inked a partnership deal with WakeMed Health & Hospitals.

Through the deal, the groups will develop a center which aims to advance clinical robotics research and train interventional cardiologists on robotic-assisted percutaneous coronary interventions using its CorPath GRX system, the Waltham, Mass.-based company said.

“Our top priority is to provide the best care possible for patients through precision medicine while protecting the physicians performing these life-saving procedures. Our partnership with leading clinical facilities such as the WakeMed Heart Center can accelerate the research, education and adoption of this important technology in cath labs across the United States,” Corindus prez & CEO Mark Toland said in a press release.

Corindus said that WakeMed Health & Hospitals has purchased 3 CorPath GRX Systems to develop a vascular robotics program. The CorPath GRX is designed to assist cardiologists in performing percutaneous coronary interventions, including angioplasty and stent placement.

“I am proud to be part of a health system that represents the best training, the latest technologies and the highest commitment to patient care, safety and innovation CorPath GRX will transform the way we perform PCI, improving care and quality of life for our patients. I look forward to partnering with Corindus to build best-in-class medical education to train physicians and staff, to advance the body of clinical research on robotics, and to help shape the robotic system of the future,” Dr. Frances Wood of the WakeMed Heart Center said in a prepared statement.

Late last month, Boston Scientific (NYSE:BSX) got in on a $45 million private placement for Corindus and the robotic GRX device it’s developing for cardiac and peripheral vascular procedures.

New investors BioStar Ventures, Consonance Capital and Hudson Executive Capital also participated, joining existing backers HealthCor Partners Management and Royal Philips (NYSE:PHG). Corindus said it expects to close the funding round this month.

The company won FDA 510(k) clearance for the next-gen CorPath GRX system last October, adding several features including the ability to control the guide catheter in 1mm increments to precisely position balloon or stent catheters during percutaneous coronary interventions.